{"url_path":"/sec/sgmo/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001628280-26-035067-index.html","accession_number":"0001628280-26-035067","cik":"0001001233","ticker":"SGMO","issuer_name":"SANGAMO THERAPEUTICS, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001628280-26-035067-index.html","primary_entity_key":"0001001233","primary_entity_name":"SANGAMO THERAPEUTICS, INC"},"word_count":366,"has_tables":true,"body_markdown":"ITEM  6.    EXHIBITS\n\nExhibit numberDescription of Document\n\n3.1\n[Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed June 2, 2023).](https://www.sec.gov/Archives/edgar/data/1001233/000162828023020692/sgmo-20230602xex33.htm)\n\n3.2\n[Certificate of Amendment of the Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 5, 2024).](https://www.sec.gov/Archives/edgar/data/1001233/000162828024026903/sgmo-20240605xex31.htm)\n\n3.3\n[Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed December 19, 2022).](https://www.sec.gov/Archives/edgar/data/1001233/000162828022032209/sgmo-20221219xxex31fifth.htm)\n\n31.1+\n[Rule 13a — 14(a) Certification of Principal Executive Officer.](sgmo-20260331xex311.htm)\n\n31.2+\n[Rule 13a — 14(a) Certification of Principal Financial Officer.](sgmo-20260331xex312.htm)\n\n32.1+*\n[Certifications Pursuant to 18 U.S.C. Section 1350.](sgmo-20260331xex321.htm)\n\n101.INS**Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH**Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.\n\n104\nThe cover page from Sangamo’s Quarterly Report on Form 10-Q for the three months ended March 31, 2026 is formatted in Inline XBRL Taxonomy Extension and it is contained in Exhibit 101.\n\n_____________________________\n\n*     The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.\n\n**    Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.\n\n+    Filed herewith.\n\n#    Indicates management contract or compensatory plan.\n\n38\n\n[Table of](#i37464b938c124fd1bcf924f2adb6d3e2_7)[Contents](#i37464b938c124fd1bcf924f2adb6d3e2_7)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nDated: May 14, 2026\n\nSANGAMO THERAPEUTICS, INC.\n\n/s/ ALEXANDER D. MACRAE\n\nAlexander D. Macrae\n\nPresident and Chief Executive Officer\n\n(Principal Executive Officer)\n\n/s/ NIKUNJ JAIN\n\nNikunj Jain\n\nInterim Chief Financial Officer\n\n(Principal Financial and Accounting Officer)\n\n39"}